Table 2.

Comparison of BCVA, corneal transparency, ocular irritation symptoms, corneal thickness, primary disease control rate and postoperative survival rate in the AMP and APCS-PP-DALK groups.

Variables	AMP group (n = 24)	APCS-PP-DALK group (n = 20)	P-value
BCVA (logMAR, mean ± SD)			0.029#
Postoperative month 1	1.48 ± 0.59	1.68 ± 0.53
Postoperative month 3	1.41 ± 0.58	1.48 ± 0.48*
Postoperative month 6	1.34 ± 0.60*	1.39 ± 0.47*
Postoperative month 12	1.32 ± 0.61*	1.33 ± 0.46*
Corneal transparency
Postoperative month 1	3.00 (3.00, 4.00)	2.00 (1.00, 2.00)	<0.001
Postoperative month 3	3.00 (3.00, 3.75)	2.00 (1.00, 2.00)	<0.001
Postoperative month 6	3.00 (2.00, 3.00)	2.00 (2.00, 2.75)	0.027
Postoperative month 12	2.00 (2.00, 3.00)	2.00 (1.25, 3.00)	0.138
Ocular irritation symptoms
Postoperative month 1	1.00 (1.00, 2.00)	2.00 (1.00, 2.75)	0.024
Postoperative month 3	1.00 (0.00, 1.75)	2.00 (1.00, 2.00)	0.033
Postoperative month 6	1.00 (0.25, 2.00)	2.00 (1.00, 2.75)	0.026
Postoperative month 12	1.00 (0.00, 1.75)	0.00 (0.00, 1.75)	0.124
Corneal thickness (μm, mean ± SD)
Pre-operation	108.96 ± 9.58	112.95 ± 19.59	0.383
Post-operation	397.1 ± 37.32*	514.7 ± 23.73*	<0.001
Primary disease control rate (n, %)	21 (87.5)	17 (85.0)	0.810
Postoperative survival rate (n, %)	21 (87.5)	17 (85.0)	0.844

^*P < 0.05, within-group difference from pre-operative baseline. ^#Group × time interaction effect from repeated measures ANOVA. BCVA, best-corrected visual acuity.